头孢替洛尔、艾拉环素和亚胺培南对鲍曼不动杆菌临床分离株的体外抗菌活性
{"_":"In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant Clinical Isolates.","i":["Acinetobacter baumannii"]}
摘要(中文译文)
是医疗保健相关感染的主要病因之一，且常与多重耐药相关，严重限制了治疗选择。碳青霉烯耐药鲍曼不动杆菌（CRAB）流行率的不断上升，激发了人们对头孢地尔、依拉环素和亚胺培南-瑞来巴坦等新型抗菌药物的兴趣。共纳入2019年4月至2023年10月期间从各类临床标本中分离的80株多重耐药（MDR）鲍曼不动杆菌分离株。按照EUCAST和CLSI建议，采用纸片扩散法、梯度试验和肉汤微量稀释法进行抗菌药物敏感性试验。头孢地尔的最低抑菌浓度（MIC）以铁耗竭阳离子调节Mueller-Hinton肉汤肉汤微量稀释法作为参考方法进行检测。通过聚合酶链反应检测碳青霉烯耐药相关基因（OXA-23、OXA-24、OXA-51、OXA-58、IMP和）的存在情况。所有分离株均对亚胺培南和美罗培南耐药。7.5%的分离株检出黏菌素耐药。根据EUCAST标准，微量稀释法显示77.5%的分离株对头孢地尔敏感，纸片扩散法显示81.25%敏感。依拉环素显示出较低的MIC值，MIC和MIC分别为0.25 mg/L和0.75 mg/L。相比之下，所有分离株均对亚胺培南-瑞来巴坦耐药。82.5%的分离株检出OXA-23基因，17.5%检出OXA-24，而未检出OXA-58、IMP或基因。头孢地尔耐药与OXA型碳青霉烯酶基因之间未发现统计学显著关联。头孢地尔和依拉环素对MDR鲍曼不动杆菌（包括黏菌素耐药分离株）显示出良好的体外活性，而亚胺培南-瑞来巴坦则无活性。这些发现支持头孢地尔和依拉环素作为CRAB感染替代治疗选择的潜在作用，并强调了头孢地尔耐药的多因素性质，其不仅限于OXA型碳青霉烯酶的产生。
Abstract
: is a leading cause of healthcare-associated infections and is frequently associated with multidrug resistance, severely limiting therapeutic options. The increasing prevalence of carbapenem-resistant (CRAB) has intensified interest in novel antimicrobial agents such as cefiderocol, eravacycline, and imipenem-relebactam. : A total of 80 multidrug-resistant (MDR) isolates recovered from various clinical specimens between April 2019 and October 2023 were included. Antimicrobial susceptibility testing was performed using disk diffusion, gradient test, and broth microdilution methods in accordance with EUCAST and CLSI recommendations. The minimum inhibitory concentrations (MIC's) for cefiderocol were evaluated with broth microdilution using iron-depleted cation-adjusted Mueller-Hinton broth as the reference method. The presence of carbapenem resistance-associated genes (OXA-23, OXA-24, OXA-51, OXA-58, IMP, and ) was investigated by polymerase chain reaction. : All isolates were resistant to imipenem and meropenem. Colistin resistance was detected in 7.5% of isolates. According to EUCAST criteria, cefiderocol susceptibility was observed in 77.5% of isolates by microdilution and in 81.25% by disk diffusion. Eravacycline demonstrated low MIC values, with MIC and MIC of 0.25 mg/L and 0.75 mg/L, respectively. In contrast, all isolates were resistant to imipenem-relebactam. The OXA-23 gene was detected in 82.5% and OXA-24 in 17.5% of isolates, while no OXA-58, IMP, or genes were identified. No statistically significant association was found between cefiderocol resistance and OXA-type carbapenemase genes. : Cefiderocol and eravacycline demonstrated promising in vitro activity against MDR , including colistin-resistant isolates, whereas imipenem-relebactam showed no activity. These findings support the potential role of cefiderocol and eravacycline as alternative treatment options for CRAB infections and highlight the multifactorial nature of cefiderocol resistance beyond OXA-type carbapenemase production.
如何引用
AMA
Yasemin Bölükbaşı, Betigül Öngen. {"_":"In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant Clinical Isolates.","i":["Acinetobacter baumannii"]}. Antibiotics (Basel, Switzerland). 2026; doi:10.3390/antibiotics15030246.
APA
Yasemin Bölükbaşı, Betigül Öngen (2026). {"_":"In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant Clinical Isolates.","i":["Acinetobacter baumannii"]}. Antibiotics (Basel, Switzerland). https://doi.org/10.3390/antibiotics15030246
GB/T 7714
Yasemin Bölükbaşı, Betigül Öngen. {"_":"In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant Clinical Isolates.","i":["Acinetobacter baumannii"]}[J]. Antibiotics (Basel, Switzerland), 2026 doi:10.3390/antibiotics15030246.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出